New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 8, 2014, Pages 2118-2122

  Malet, Isabelle ^a,b,c   Arriaga, Laura Gimferrer ^a,b,c   Artese, Anna ^d   Costa, Giosue' ^d   Parrotta, Lucia ^d   Alcaro, Stefano ^d   Delelis, Olivier ^e   Tmeizeh, Ahmed ^a,b,c   Katlama, Christine ^a,b,c   Valantin, Marc Antoine ^a,b,c   Ceccherini Silberstein, Francesca ^f   Calvez, Vincent ^a,b,c   Marcelin, Anne Genevie've ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^e Ecole Normale Superieure de Cachan   (France)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Binding affinity; Dolutegravir; Elvitegravir; Phenotype; Raltegravir

Indexed keywords

DOLUTEGRAVIR; ELVITEGRAVIR; HYDROGEN; INTEGRASE; INTEGRASE INHIBITOR; RALTEGRAVIR; 2 PYRROLIDONE DERIVATIVE; FUSED HETEROCYCLIC RINGS; PROTEIN BINDING; QUINOLONE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; BINDING AFFINITY; COMPUTER MODEL; CROSS RESISTANCE; DRUG STABILITY; DRUG TREATMENT FAILURE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYDROGEN BOND; PHENOTYPE; THERMODYNAMICS; WILD TYPE; AMINO ACID SUBSTITUTION; DRUG EFFECTS; GENETICS; HIV INFECTIONS; MUTATION; TREATMENT FAILURE; VIROLOGY;

AMINO ACID SUBSTITUTION; DRUG RESISTANCE, VIRAL; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MUTATION; PROTEIN BINDING; PYRROLIDINONES; QUINOLONES; TREATMENT FAILURE;

EID: 84904559099     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku095     Document Type: Article

References (20)

1. Cooper DA, Steigbigel RT, Gatell JM et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359: 355-65.
2. Delelis O, Thierry S, Subra F et al. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob Agents Chemother 2010; 54: 491-501.
3. Goethals O, Clayton R, Van Ginderen M et al. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 2008; 82: 10366-74.
4. Malet I, Delelis O, Valantin MA et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008; 52: 1351-8.
5. Shimura K, Kodama E, Sakagami Y et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008; 82: 764-74.
6. Bar-Magen T, Sloan RD, Donahue DA et al. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol 2010; 84: 9210-6.
7. Kobayashi M, Yoshinaga T, Seki T et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011; 55: 813-21.
8. Vavro C, Huang J, Underwood M et al. Integrase genotypic and phenotypic predictors of antiviral response to dolutegravir (DTG) in subjects with resistance to integrase inhibitors (INIs). In: International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies, Toronto, ON, Canada, 2013. Abstract 29.
9. Barreca ML, Iraci N, De Luca L et al. Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors. ChemMedChem 2009; 4: 1446-56.
10. Sherman W, Day T, Jacobson MP et al. Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 2006; 49: 534-53.
11. Maestro. New York: Schrödinger, LLC, 2012.
12. Jorgensen WL, Maxwell DS, Tirado-Rives J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 1996; 118: 11225-36.
13. Liaison. New York, NY: Schrödinger, 2012.
14. Banks JL, Beard HS, Cao Y et al. Integrated Modeling Program, Applied Chemical Theory (IMPACT). J Comput Chem 2005; 26: 1752-80.
15. Malet I, Soulie C, Tchertanov L et al. Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases. J Med Virol 2008; 80: 754-61.
16. Quashie PK, Mesplede T, Han YS et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 2012; 86: 2696-705.
17. Malet I, Fourati S, Charpentier C et al. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. J Antimicrob Chemother 2011; 66: 2827-30.
18. Rowley M. The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection. Prog Med Chem 2008; 46: 1-28.
19. Souza Cavalcanti J, Minhoto Lanca A, Paula Ferreira JL et al. In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen. Antiviral Res 2012; 95: 9-11.
20. Eron JJ, Clotet B, Durant J et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 2013; 207: 740-8.